These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29439221)

  • 1. Gene therapy field hit by fresh safety concern.
    Kaiser J
    Science; 2018 Feb; 359(6376):621. PubMed ID: 29439221
    [No Abstract]   [Full Text] [Related]  

  • 2. A second chance.
    Kaiser J
    Science; 2017 Nov; 358(6363):582-585. PubMed ID: 29097531
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy S; Shell R; Arnold WD; Rodino-Klapac LR; Prior TW; Lowes L; Alfano L; Berry K; Church K; Kissel JT; Nagendran S; L'Italien J; Sproule DM; Wells C; Cardenas JA; Heitzer MD; Kaspar A; Corcoran S; Braun L; Likhite S; Miranda C; Meyer K; Foust KD; Burghes AHM; Kaspar BK
    N Engl J Med; 2017 Nov; 377(18):1713-1722. PubMed ID: 29091557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.
    Waldrop MA; Karingada C; Storey MA; Powers B; Iammarino MA; Miller NF; Alfano LN; Noritz G; Rossman I; Ginsberg M; Mosher KA; Broomall E; Goldstein J; Bass N; Lowes LP; Tsao CY; Mendell JR; Connolly AM
    Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32843442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zolgensma - one-time gene therapy for spinal muscular atrophy.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
    Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
    Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy Briefs.
    Philippidis A
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):167-174. PubMed ID: 29243984
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply: To PMID 23893312.
    Kang PB; Gooch CL; McDermott MP; Darras BT; Finkel RS; Yang ML; Sproule DM; Chung WK; Kaufmann P; De Vivo DC;
    Muscle Nerve; 2014 Sep; 50(3):458-9. PubMed ID: 24935909
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances and challenges in developing a therapy for spinal muscular atrophy.
    Anderton RS; Mastaglia FL
    Expert Rev Neurother; 2015; 15(8):895-908. PubMed ID: 26200127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Treleaven CM; Sullivan JA; O'Riordan CR; Scaria A; Kells AP; Samaranch L; San Sebastian W; Federici T; Fiandaca MS; Boulis NM; Bankiewicz KS; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2014 Jul; 25(7):619-30. PubMed ID: 24617515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pictorial essay of Werdnig-Hoffman disease.
    Poggiani C; Ferrari D; Parati S; Torresani P
    Minerva Pediatr; 2009 Apr; 61(2):237-8. PubMed ID: 19322128
    [No Abstract]   [Full Text] [Related]  

  • 12. An infant with spinal muscular atrophy and tetrology of Fallot.
    Ekici B; Demir IH; Ocak S; Yeşil G; Tatlı B; Çelebi A
    Clin Neurol Neurosurg; 2012 Sep; 114(7):1033-4. PubMed ID: 22366241
    [No Abstract]   [Full Text] [Related]  

  • 13. Spinal muscular atrophy: recent advances and future prospects.
    Nicole S; Diaz CC; Frugier T; Melki J
    Muscle Nerve; 2002 Jul; 26(1):4-13. PubMed ID: 12115944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of SMA type 1 infants using a single-dose AAV9-mediated gene therapy via intrathecal injection of GC101: An open-label, single-arm study.
    Ma X; Zhuang L; Ma W; Li J; Wang X; Li Z; Jiang X; Wang Y; Du Y; Zhang Y; He F; Zhu Z; Du S; Xu J; Gu R; Zhang Y; Zhang S; Li T; Yang X; Zhang S; Zhu L; Li Q; Dong X; Wu X; Feng Z
    Chin Med J (Engl); 2024 Aug; 137(16):1976-1978. PubMed ID: 39030070
    [No Abstract]   [Full Text] [Related]  

  • 15. Double trouble: spinal muscular atrophy type II and seropositive myasthenia gravis in the same patient.
    Jokela M; Udd B; Päivärinta M
    Neuromuscul Disord; 2012 Feb; 22(2):129-30. PubMed ID: 21862330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastoma in a Patient With Spinal Muscular Atrophy Type I: Is It Just a Coincidence?
    Sag E; Sen HS; Haliloglu G; Yalcin B; Kutluk T
    J Child Neurol; 2015 Jul; 30(8):1075-8. PubMed ID: 25123529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal muscular atrophy due to double gene conversion event.
    Maamouri W; Hammer MB; Bouhlel Y; Souilem S; Khmiri N; Nehdi H; Hentati F; Amouri R
    Int J Neurosci; 2011 Feb; 121(2):107-11. PubMed ID: 21047176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Toxicity in Nonhuman Primates and Piglets with Systemic High-Dose Administration of Adeno-Associated Virus Serotype 9-Like Vectors: Putting Patients First.
    Flotte TR; Büning H
    Hum Gene Ther; 2018 Mar; 29(3):283-284. PubMed ID: 29378415
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials in spinal muscular atrophy.
    Darras BT; Kang PB
    Curr Opin Pediatr; 2007 Dec; 19(6):675-9. PubMed ID: 18025935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.